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ABSTRACT 
The persistence of attention-deficit/hyperactivity disorder (ADHO) into 
adulthood has been increasingly recognized over the past few decades and the 
stimulant drug dl-methylphenidate (MPH) has remained a first-line 
pharmacotherapeutic agent in the treatment of ADHD. Many adult ADHD patients 
who are prescribed MPH report concomitant use with ethanol. 
In humans, coadministration of dl-MPH and ethanol results in pharmacokinetic 
and pharmacodynamic drug - drug interactions. Ethanol elevates biological 
concentrations of the pharmacologically active d-MPH isomer and yields the 
metabolic transesterification product ethylphenidate (EPH). EPH appears to be 
formed through the actions of carboxylesterase 1 (CES1) which exhibits I-MPH 
substrate enantioselectivity in both the metabolic transesterification and 
deesterification pathways. Accordingly, the mean absolute oral bioavailability of 
I-MPH is limited to only 1-3°k compared to approximately 30% for d-MPH. 
However, dosing with transdermal dl-MPH (Daytrana~ avoids the extensive oral 
presystemic metabolism and leads to approximately 50 times more I-MPH 
reaching the systemic circulation when compared with oral dosing. Studies using 
human subjects are limited in their ability to examine abuse like doses. 
Using a C57BU6J mouse model, the experiments in this dissertation were 
designed to: 1) Establish the rewarding properties and abuse potential of Lv. 
dl-MPH as evidenced by drug seeking behavior; 2) Investigate the 
pharmacokinetic interactions of dl-MPH and ethanol coabuse, placing an 
emphasis on the MPH transdermal system; 3) Investigate the pharmacodynamic 
interactions of dl-MPH and ethanol coabuse. 
The reward value of methylphenidate is evidenced by robust drug-seeking 
behavior in C57 mice, which are an appropriate model to investigate 
methylphenidate abuse liability. Pharmacokinetic studies showed that, as in 
humans, transdermal dl-MPH greatly facilitated the absorption of I-MPH in this 
mouse strain. Similarly, ethanol led to the enantioselective formation of I-EPH 
and to an elevation in d-MPH concentrations with both transdermal and oral dl-
MPH. While only guarded comparisons between transdermal and oral dl-MPH 
can be made due to route-dependent drug absorption rate differences, 
transdermal dl-MPH was associated with significant MPH - ethanol interactions. 
Pharmacodynamic studies showed that an otherwise depressive dose of ethanol 
significantly potentiated oral dl-MPH induced increases in total distance traveled 
for the first 100 min. Further, transdermal dl-MPH increased total distance 
traveled after a latency of 80 min, though this effect was not potentiated by 
concomitant ethanol. 
The results from these studies in combination with human data, provide a 
scientific basis for extending abuse precautions for the ethanol - dl-MPH 
combination in general, with a novel focus on transdermal dl-MPH. 
Chapter 1 
Introduction 
Attention-Deficit/Hyperactivity Disorder: Prevalence & Etiology 
Attention-deficit/hyperactivity disorder (ADHD) is the most commonly 
diagnosed childhood neuropsychiatric condition and the persistence of ADHD 
into adulthood is increasingly recognized [1-6]. Symptoms include inability to 
focus or pay attention, hyperactivity, and impulsive behaviors. There are 3 
subtypes of ADHD: 1) Predominantly hyperactive-impulsive, 2) Predominately 
inattentive, 3) Combined hyperactive-impulse and inattentive [7]. In the 
United States, the lifetime prevalence for children and adolescents has been 
estimated to range upward to 9.00/0 [8]; and for adults the incidence appears 
to exceed 4% [9]. Boys are significantly more likely to be diagnosed with 
ADHD than girls [10], however recent studies suggest that this phenomenon 
could be in part due to subjectivity in referrals made by teachers [11]. 
There is no single cause for ADHD, however a number of factors can 
contribute to or worsen ADHD symptoms. These factors include: a genetic 
predisposition where prominent candidate genes include those expressing the 
D4 postsynaptic dopamine receptor and/or the presynaptic dopamine 
transporter (OAT), poor diet, neurochemical imbalances, e.g., dopamine 
and/or norepinephrine, and the social/physical environment. 
Treatments 
Following a diagnosis of ADHD, most patients undergo a combination 
of behavioral modifications and pharmacotherapy. There are two non-
stimulant medications that are FDA approved in the treatment of ADHD, 
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atomoxetine (Strattera®) and guanfacine (Intuniv®). Atomoxetine is a 
selective norepinephrine reuptake inhibitor that is not a controlled substance, 
however disadvantages include rare, but severe, liver damage and suicide 
ideation [12]. Further, this drug is primarily metabolized by CYP2D6 whereby 
pharmacogenetic polymorphisms may become clinically significant in dose 
individualization. Guanfacine is an alpha-2 agonist and its mechanism of 
action appears to be through feedback inhibition of norepinephrine synaptic 
release. Only the extended-release formulation is FDA approved in the 
treatment of ADHD and the potential for cardiovascular side effects should be 
considered prior to use [13]. 
More commonly, ADHD patients are prescribed stimulant medications, 
e.g. methylphenidate (MPH) or amphetamine. Amphetamine is typically 
viewed as a 2nd line agent to treat ADHD not responsive to MPH. There are 
numerous amphetamine formulations used in the treatment of ADHD. These 
include "mixed amphetamine salts" composed of dl-amphetamine in an 
unusual 75% d- : 25% I-mixture of isomer; a prodrug derivative where d-
amphetamine is converted to a lysine amide for reduced abuse potential and 
reported improvement in pharmacokinetic properties; and finally formulations 
containing only the more active d-isomer of amphetamine. As with most 
stimulant medications, abuse, dependence, and cardiovascular adverse 
events are major clinical consideration in the use of ADHD stimulants [14]. 
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The racemic (50:50 mixture of enantiomers) stimulant drug dl-MPH 
(Figure 1. 1) has remained the first-line pharmacotherapeutic agent to treat 
ADHD since the 1950s [3, 15-16]. MPH is generally an effective and well 
tolerated drug in the treatment of ADHD. 
In the adult ADHD population, dl-MPH is also the most widely 
prescribed psychotherapeutic agent [5]. As a consequence, this controlled 
substance has become more widely available for abuse and diversion [17-19], 
especially among high school [20] and college students [21-22]. Appropriate 
drug therapy for an older ADHD population requires a special consideration of 
lifestyle and lifespan comorbidities [5], such as hypertension [21,23], where 
elevation of blood pressure by dl-MPH can represent a contraindication. 
H 
d-MPH 







MPH is available both as an immediate-release tablet as well as in various 
modified-release formulations. The drug is subject to extensive and 
enantioselective presystemic metabolism. In humans, oral dl-MPH dosing 
results in only -30% of the d-isomer and -1 % of the I-isomer reaching the 
systemic circulation. Mass balance studies conducted in humans and rodents 
demonstrate that -90+% of the drug is hydrolyzed to the inactive [24] 
metabolite ritalinic acid [25], -1-2% is p-hydroxylated, -5% is oxidized to the 
corresponding lactam, and -1-20/0 is excreted unchanged. MPH is not subject 
to metabolic isomerization. MPH exhibits the relatively short (2 ... 3 h) half-life of 
2-3 h largely due to the rapid hydrolysis of the methyl ester. Accordingly, most 
ADHD patients receiving immediate-release tablets require multiple daily 
doses to maintain symptom control[15]. This creates many issues related to 
convenience, compliance, peer ridicule and security of this schedule II 
narcotic, i.e., diversion. For these reasons, many MPH formulations 
incorporate a range of modified-release pharmaceutical technologies to allow 
for single daily dosing. 
In 2006, the FDA approved the first transdermal patch for the 
administration of dl-MPH (Daytrana~. Like the modified-release oral 
formulations, the transdermal patch overcomes the need for multiple daily 
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dosing regimens, in this case by delivering in continuous release of dl-MPH 
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Figure 1.2 Plasma d-MPH and I-MPH (inset) concentration profiles 
for 12.5 (0),25 (0 ), and 37.5 cm2 (~) transdermal methylphenidate 
compared to 54 mg Concerta® (X) [26]. 
This dl-MPH transdermal delivery system relies on a high load of dl-
MPH free base incorporated within a uniform blend of acrylic polymers and 
silicone adhesives to drive drug absorption based on the drug concentration 
gradient, without the need for permeability enhancers (for review see [16]) . 
Using transdermal delivery of dl-MPH circumvents the extensive and highly 
enantioselective presystemic metabolism associated with oral dosing [27-28] . 
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This results in transdermal dl-MPH producing approximately 50 times higher 
plasma I-MPH concentrations than occurs following oral dosing (Figure 1.2) 
[29]. 
Methylphenidate: Interactions with Ethanol 
Optimized adult ADHD pharmacotherapy may be complicated by 
alcohol consumption, alcohol use disorder (AUD) or other substance use 
disorders (SUD). SUD are over-represented in adult ADHD [1, 30-31]. The 
rewarding properties of dl-MPH have not been fully characterized and in light 
of the significant over-representation of SUD, e.g., AUD in adult ADHD, first 
line therapies such as dl-MPH require investigation of their abuse potential in 
the context of ethanol use and misuse. 
In drug diversion, dl-MPH is reported to be co-abused with ethanol in 
the majority of users surveyed [18]. . Not surprisingly, dJ-MPH related 
emergency department visits number in the thousand each year [19]. 
Accordingly, prescribing dl-MPH has generated special concern regarding 
concomitant ethanol use or abuse [32-34]. This concern stems from the co-
abuse of cocaine and ethanol as a precedent. Cocaine and methylphenidate 
are similar in their pharmacokinetic and pharmacodynamic profiles, where 
both increase extracellular dopamine through blockade of the OAT as well as 
increasing subjective reports of feeling "high" [18]. Both drugs contain a 
methyl ester metabolized by carboxylesterase 1 yielding a carboxylic acid 
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metabolite and, upon coadministration of ethanol, a transesterification 
metabolite [35]. 
Thus, coadministration of ethanol and dl-MPH orally to humans [27, 
36] results in a drug - drug interaction where the methyl ester of MPH is 
transesterified to yield ethylphenidate (EPH; Figure 1.2) [27]. Both EPH and 
ritalinic acid formation appear to be primarily mediated by the actions of 
carboxylesterase 1 (CES1) [37-39] which exhibit I-MPH substrate 





Figure 1.2 Metabolic fate of dl-MPH with or without ethanol. 
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Any I-MPH, or the metabolite I-EPH, which reaches system circulation 
is unlikely to contribute directly to the pharmacodynamics of the dl-MPH -
ethanol interaction in view of the findings that only the d-isomers of MPH and 
EPH possess potent effects on dopaminergic and noradrenergic systems [40-
41]. 
In a recent human study, coadministration of dl-MPH and ethanol 
resulted in a significant elevation of maximum plasma d-MPH concentrations 
(Cmax) and overall d-MPH exposure [27]. Elevated plasma d-MPH 
concentrations increase the potential for adverse cardiovascular events [42-
43] due to the fact ·that the d-isomer is responsible for adrenergic pressor 
effects. In addition to the influence of ethanol on dl-MPH pharmacokinetics, 
the above normal subjects reported an increase in pleasurable effects when 
combining dl-MPH with ethanol [44]. Such positive subjective effects may 
predispose individuals to greater abuse liability [32-33, 45]. The enhanced 
reward value of this drug combination may be based on interactive effects of 
these two psychoactive drugs on excitatory neural systems as recently been 
reported using a C57 mouse behavioral model [46]. Further, these increased 
effects may also pertain to the elevated rate at which d-MPH reaches the 
bloodstream, a temporal aspect associated with abuse potential [47-49]. 
Thus, when dl-MPH is combined with ethanol, the time to maximum 
concentration (T max) occurs at the same time as dl-MPH dosed alone, 
however, the Cmax has been found to be significantly higher at this time [27]. 
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Societal/medical Implications of MPH-ethanol Interactions 
There is an increasing number of adults being diagnosed with ADHD 
and most adult ADHD patients report ethanol use. Previous studies have 
shown a significant pharmacokinetic interaction between dl-MPH and ethanol 
in humans given therapeutic doses of oral dl-MPH [16, 27]. However, little 
work has addressed pharmacokinetic or pharmacodynamic interactions that 
may follow after abuse level dosing- bingeing. Further, the introduction of 
transdermal dl-MPH is of special concern due to the high levels of circulation 
I-MPH which are thought to enantioselectively interact and inhibit CES1. The 
interaction with ethanol could significantly alter the therapeutic effects of dl-
MPH or contribute to side effects. 
Therefore, the experiments described in this dissertation were 
designed to specifically address the following: 
Specific Aim 1. Establish the rewarding properties of dl-MPH as evidenced 
by drug seeking behavior in a C57 mouse model. 
1A. Determine if C57 mice will self-administer dl-MPH. 
1 B. Examine the drug seeking behavior of C57 mice for dl-MPH 
following increasingly difficult behavioral demands. 
1C. Determine the maintenance of drug seeking behavior following a 
two week abstinence of any drug or cue. 
Specific Aim 2. Investigate the effects of ethanol on the concentration of d-
MPH and 1- MPH in the blood, brain and urine of C57 mice. 
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2A. Develop new enantiospecific analytical methodology to establish 
the dose delivered by transdermal dosing for oral dose selection. 
28. Analyze brain, blood and urine concentrations of d-MPH and 1-
MPH following oral and transdermal dosing applying novel 
enantiospecific methodologies. 
2C. Analyze micro-samples of brain, blood and urine for concentrations 
of d-MPH and 1- MPH following an oral dl-MPH dose that reflects a 
comparable transdermal dose. 
Specific Aim 3. Investigate stimulant effects of dl-MPH with or without ethanol 
on the locomotor activity of C57 mice. 
3A. Develop methodology for analyzing locomotor activity of C57 mice 
given dl-MPH transdermally compared to oral dosing. 
3B. Establish the interactive effects of ethanol and transdermal dl-
MPH on the locomotor activity of C57 mice. 
3C. Examine the interactive effects of ethanol and oral dl-MPH on the 
locomotor activity of C57 mice. 
The results from these animal investigations will be discussed with a 
translational focus regarding the rational individualization of drug selection for 




Reward value of methylphenidate in C57BU6J mice 
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Introduction 
The stimulant MPH provides a first-line pharmacotherapy for ADHD in 
both children and adults. There have been few animal studies modeling the 
abuse potential of MPH in the context of its reward properties. The 
Spontaneously Hypertensive Rat has been used in efforts to model the 
ameliorating effects of MPH on ADHD-like behaviors. While this rat appears 
to exhibit drug seeking behavior [50], other lines of evidence reveal that this 
particular rat does not model the control of ADHD symptoms by MPH [51-52]. 
Other studies using the Sprague-Dawley rat show that they also exhibit drug 
seeking behavior in response to MPH [53] and the response of this strain to 
stimulants of abuse has been well characterized. The current study aims to 
characterize the reward value of MPH in a novel mouse model. 
Self-administration is an operant conditioning approach that gauges 
the reward properties of a particular drug. Typically, the test drug is 
administered intravenously. It is a widely utilized and well validated model of 
drug addiction liability and abuse potential. Reinstatement of drug seeking 
behavior after an extended abstinence period indicates the extent of addiction 
liability/reward value of the drug evaluated. Accordingly, we used this 
approach in the present study to measure the reward value of MPH in a novel 
C57BU6J (C57) mouse model. The C57 mouse strain was chosen based on 
its frequent use as a reference strain in preclinical psychopharmacology of 
stimulant agents; including MPH [40, 46, 54-55]. Further, C57 mice have 
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been shown to self-administer cocaine [56] as well as reinstate cocaine 
seeking behavior in response to conditioned stimuli [57]. Cocaine is similar to 
MPH in its pharmacodynamic [58] and pharmacokinetic [35] characteristics, 
therefore we hypothesize that C57 mice will self-administer MPH and will act 
as a useful animal model for ongoing studies of MPH drug abuse 
pharmacology. 
Materials and Methods 
Animals 
Experimentally na"ive C57 male mice (n=8, 6-8 weeks old, Jackson 
Laboratories) were individually housed in an AALAC accredited animal facility 
and were maintained on a 12 h light cycle (lights on at 0600h). Behavioral 
testing occurred during the dark phase of their circadian cycle. The mice had 
free access to water, and food was restricted to maintain bodyweights at 900/0 
of ad libitum weight after the jugular catheterization surgery. All experimental 
protocols were approved by the Institutional Animal Care and Use Committee 
and were consistent with the guidelines of the NIH Guide for the Care and 
Use of Laboratory Animals (NIH Publication No. 80-23, revised 1996). 
Catheter Surgery 
Mice were anaesthetized using gaseous isofluorane. Chronic 
indwelling catheters were designed and constructed for insertion into the right 
jugular vein with a skull-mounted access port as previously reported [56, 59]. 
Catheters were flushed daily with 0.1 mL of antibiotic (Cefazolin) followed by 
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0.1 mL of heparin. Mice were given 2 days for postoperative recovery before 
experimentation. Catheter patency was tested by injecting 0.1 mL of 
thiopental sodium on the day before and the last day of self-administration 
testing. Mice that did not lose muscle tone within 2-3 sec were excluded from 
the experiment. 
Self-administration 
Self-administration training was conducted during 2 h sessions on 
consecutive days. The self-administration chambers (Med Associates, Inc., 
Georgia, VT, model ENV-307A) were enclosed in sound attenuating cabinets. 
Presentation of stimuli and data collection was controlled by MedPC software. 
Catheters were connected to liquid swivels via silastic tubing. The swivels 
were suspended above the operant conditioning chamber and were 
connected to infusion pumps. Two response levers were located 6.5 em 
above the grid floor on the same wall of the chamber. A reinforced response 
on the active lever resulted in 1) termination of the red house light, 2) initiation 
of a 2 sec compound conditioned stimulus consisting of a tone (2,900 Hz, 
ENV-323A), a white LED stimuli light (ENV-321 M) located directly above the 
active lever, and the infusion pump noise, and 3) infusion of 0.1 mg/kg of 
MPH. Mice were first trained to press a lever according to a fixed ratio (FR) 1 
schedule of MPH reinforcement with 2 sec time-out period. During the 
sessions, responses on the inactive lever had no programmed consequences 
but were recorded. Active and inactive lever assignments were randomized. 
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Daily self-administration training sessions were continued until the mouse 
reached the acquisition criterion (i.e. ~ 10 infusions self-administered per 
session on a minimum of 5 consecutive training days). After acquisition on an 
FR1 schedule, mice were trained on an FR2 schedule using the same criteria 
and consequences for lever pressing. Following acquisition on an FR2 
schedule, mice were finally trained on a progressive ratio (PR) 2 schedule 
using the same criteria and consequences for lever pressing. 
Abstinence 
Mice were maintained in their home cages for 14 consecutive days 
with food and water ad libitum. 
Reinstatement testing 
The first reinstatement test was conducted on an FR1 schedule, the 
second was conducted on an FR2 schedule, and the third was conducted on 
a PR2 schedule. During the test sessions, mice were connected to the 
silastic tubing previous used to deliver drug and lever presses were recorded 
for 2 h on the previously active and inactive levers with the tone and light 
consequences, but without any drug delivery. 
Cue-less training 
Mice were placed in the operant chamber for 2 h sessions for 2 weeks 
and there were no programmed consequences for either lever. 
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Statistical Methods 
Repeated measures analyses of variance (ANOVA) were used to 
analyze MPH intake and lever responses. Lever (active vs. inactive) and day 
(self-administration, reinstatement, cue-less) were included as repeated 
measured factors. Statistical analysis was conducted using SPSS 12.0 
(SPSS I.; Chicago, Illinois, USA). Statistically significant interaction effects 
were further investigated using Tukey post-hoc tests. 
Results 
All test animals met training criteria on an FR1 schedule within 10 days 
of the initial testing session demonstrating that C57 mice will self-administer 
MPH and acquire self-administration quickly as shown by mean lever presses 
on the active lever being significantly greater than the inactive lever. 
Moreover, self-administration of MPH was maintained despite increasingly 
difficult behavioral demands (Figure 2.1). 
Following a 2 week abstinence period, lever pressing significantly 
increased on both the active and inactive levers during reinstatement training 
compared to the final training session at an FR 2 schedule (Figure 2.2). 
Further, the ratio of reinstatement over training mean lever presses on the 
active lever was significantly greater showing an increase in reward value 
through drug seeing behavior. 
Removing the light and tone cues attenuated mean lever presses on 
both the active and inactive levers, but did not completely eliminate drug 
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seeking behavior implying that the drug seeking behavior is not simply a 
response to conditioned cues (Figure 2.3). Drug seeking behavior was 
significantly decreased during a cue-less testing session compared to a 
reinstatement testing session on an FR2 schedule. 
Discussion 
Previous studies using the spontaneously hypertensive rat as a model 
for ADHD show that they do exhibit drug seeking behavior [50]. However, 
growing evidence suggests that this rat is quite limited as an appropriate 
model for ADHD, particularly in their response to first-line therapeutic agent 
MPH [51-52]. The C57 mouse is a widely used reference strain for drugs of 
abuse [40-41 , 46, 55]. C57 mice have been shown to self-administer cocaine 
[56] and in the present study have been shown to quickly acquire drug 
seeking behavior of MPH. Further, self-administration was maintained despite 
increasingly difficult demands. The special reward value of MPH is revealed 
through the robust drug-seeking behavior recorded, despite a two week 
abstinence period and the lack of drug reinforcement. In addition, we have 
demonstrated the maintenance of drug seeking behavior despite removal of 
condition cues which implies that the drug seeking behavior in this study was 
not based on a conditioned response, but rather due to the reward value of 
MPH itself. Our findings add support for the use of C57 mice as an 
appropriate reference stain and species to characterize MPH 




Mean lever presses on the active lever were significantly greater than the 
inactive lever on days 5-20. (all p>O.001) 
Figure 2.2 
Mean lever presses on both the active and inactive levers were significantly 
increased (*p<O.001) during reinstatement testing following a two week 
abstinence period. 
Figure 2.3 
Mean lever responses on both the active and inactive levers significantly 
decreased when the conditioned stimuli were removed, but were not 
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Chapter 3 
Transdermal and oral dl-MPH - ethanol interactions in C57BU6J mice: 




ADHD is the most commonly diagnosed childhood neuropsychiatric 
condition. The stimulant drug dl-MPH has remained a first-line 
pharmacotherapeutic agent to treat ADHD since the 1950s [3, 15-16]. 
Further, the persistence of ADHD into adulthood is increasingly recognized 
[1-6]. In the adult ADHD population, dl-MPH is also the most widely 
prescribed psychotherapeutic agent [5]. As a consequence, this controlled 
substance has become more widely available for abuse and diversion [17-19], 
especially among high school [20] and college students [21-22]. 
Appropriate drug therapy for this older ADHD population requires a 
special consideration of lifestyle and lifespan comorbidities [5], such as 
hypertension [21, 23]. Optimized adult ADHD pharmacotherapy may be 
complicated by alcohol consumption, alcohol use disorder (AUD) or other 
substance use disorders (SUD). Both AUD and SUD are over-represented in 
adult ADHD [1, 30-31], especially in women [60]. Not surprisingly, given the 
clinical nature of adult ADHD [61], and the susceptible population for which 
MPH is prescribed [1], dl-MPH related emergency department visits have 
numbered in the thousands each year, e.g., 8,000 for 2004 [19]. Moreover, 
emergency room presentations for incidents involving alcohol in combination 
with drugs have risen 63% for persons aged 18 to 19 years, and have 
increased 100% for persons age 45-54 [62]. Poison center data reveal how 
extensive dl-MPH abuse has become [19, 63-66]. In a drug diversion context, 
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ADHD stimulants are often co-abused with ethanol, e.g., in 53% of those 
surveyed [67]; and dl-MPH in particular has been reported to be co-abused 
with ethanol in 92% of those surveyed [18]. Accordingly, prescribing or 
diverting psychostimulants has generated special concern regarding 
concomitant ethanol use or abuse [32-34]. 
These statistics are consistent with MPH being classified as a DEA 
schedule II controlled substance [68], i.e., a medication of very high abuse 
potential [44, 69-70]. Accordingly, the prevalence and inherent danger of 
concomitant dl-MPH and ethanol warrant research into the pharmacology of 
this drug combination. 
Coadministration of ethanol and dl-MPH orally to humans [27, 36] 
results in a drug - drug interaction where the methyl ester of MPH is 
transesterified to yield ethylphenidate (EPH; Figure 3.1) [27] in addition to 
being hydrolyzed to the inactive [24] metabolite ritalinic acid [25]. Both EPH 
and ritalinic acid formation appear to be primarily mediated by the actions of 
carboxylesterase 1 (CES1) [37-39] which exhibits I-MPH substrate 
enantioselectivity in both the transesterification and hydrolysis pathways [27, 
40). 
The metabolic transesterification of dl-MPH with ethanol to yield EPH 
was first reported in vitro using rat microsomes [71]. Subsequently, EPH was 
detected in human tissues from two fatal drug overdoses in which unknown 
amounts of MPH and ethanol were consumed [72]. These findings prompted 
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a normal human volunteer pilot study of the dl-MPH - ethanol interaction [73], 
followed by a larger human study where enantiospecific methodology for 
plasma analysis was utilized [44]. In this latter study, it was established that 
the dl-MPH - ethanol transesterification pathway primarily yields the 1-
enantiomer of EPH (Figure 3.1). 
Any I-MPH, or the metabolite I-EPH, which reaches the bloodstream is 
unlikely to contribute directly to the pharmacodynamics of the dl-MPH -
ethanol interaction in view of the findings that only the d-isomers of MPH and 
EPH possess potent effects on dopaminergic and noradrenergic systems [40-
41]. This notwithstanding, ethanol consumed with dl-MPH by normal human 
volunteers resulted in a significant elevation of maximum plasma d-MPH 
concentrations (Cmax) and overall d-MPH exposure [27]. Elevated plasma d-
MPH concentrations increase the potential for adverse cardiovascular events, 
especially in ADHD patients with comorbid hypertension [42-43]. 
In addition to the influence of ethanol on dl-MPH pharmacokinetics, the 
above normal subjects reported an increase in pleasurable effects when 
combining dl-MPH with ethanol [44]. Such positive subjective effects may 
predispose individuals to greater abuse liability [32-33, 45]. The enhanced 
likability of this drug combination may be based on interactive effects of these 
two psychoactive drugs on excitatory neural systems as recently reported 
using a C57BUJ6 (C57) mouse behavioral model [46]. However, the 
increased likability may also pertain to the elevated rate at which d-MPH 
26 
reaches the bloodstream [47-49]. When dl-MPH is combined with ethanol, the 
time to maximum concentration (T max) occurs at the same time as dl-MPH 
dosed alone. However, the Cmax is much higher at this time following 
concomitant dl-MPH and ethanol than when dl-MPH is dosed alone [27]. 
In 2006, the FDA approved the first transdermal patch for the 
administration of dl-MPH (Daytrana~. This dl-MPH transdermal delivery 
system (MTS) relies on a high load of dl-MPH free base incorporated within a 
uniform blend of acrylic polymers and silicone adhesives to drive drug 
absorption based on the drug concentration gradient, without the need for 
permeability enhancers (for review see [16]). Using transdermal delivery of dl-
MPH circumvents the extensive and highly enantioselective presystemic 
metabolism associated with oral dosing [27-28]. Accordingly, MTS results in 
approximately 50 times higher plasma I-MPH concentrations than occur 
following oral dosing [29]. 
The present preclinical study investigated aspects of MTS and oral 
MPH absorption and disposition as influenced by the coadministration of 
ethanol. Special attention was given to the formation of I-EPH in view of the 
relatively large amount of I-MPH anticipated to reach the bloodstream 
following MTS delivery. The C57 mouse strain was chosen based on its 
frequent use as a reference strain in preclinical psychopharmacology of 
stimulant agents; including MPH and ethanol [40-41,46, 55,74]. Further, like 
human MPH metabolism, the C57 mouse has previously been reported to 
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favor I-MPH as a substrate in the transesterification of ethanol to yield I-EPH 
after intraperitoneal (Lp.) dosing [40]. 
Blood, brain and urine concentrations of d-MPH, I-MPH, d-EPH and 1-
EPH were analyzed. The mean MTS dose delivered from a % of a 12.5 cm2 
patch (smallest of 4 sizes available) after a 3.25 h wear was calculated by 
quantifying the residual MPH content in the used patches. This dose was then 
administered for oral studies, while clearly recognizing the limitations of any 
direct drug dispositional comparisons of a bolus oral dl-MPH dose to that of 
the MTS in mice where prolonged release of drug occurs from the patch. A 
modification of an established gas chromatographic-mass spectrometric-
electron impact-selected ion monitoring (GC-MS-EI-SIM) method was used 
for these enantiospecific determinations [41, 75]. MPH and EPH enantiomers 
were derivatized with (S)-N-trifluoroacetylprolyl chloride (TFP-CI) to yield GC 
resolvable diastereomers. Piperidine-deuterated dl-MPH was incorporated for 
analytical control. 
Materials and Methods 
Materials 
Ethanol used for oral animal studies was from AAPER Alcohol and 
Chemical Co. (Shelbyville, KY; 950/0). dl-MPH·HCI used for oral animal 
studies was from Sigma-Aldrich (St. Louis, MO; lot # 118K1052) and the 12.5 
cm2 size MTS was from Shire US CVVayne, PA; lot # 2616811; smallest of 4 
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sizes available). Laboratory tape used to secure MTS or placebo was from 
WlR International (white, 12.7 mm). dl-MPH·HCI in methanol (1 mg/mL 
calculated as free base; Cerilliant, Round Rock, TX) was used as the 
analytical reference standard. The dl-EPH·HCI standard in ethanol (1 mg/mL 
calculated as free base) was synthesized in-house[41]. (S)-N-
(trifluoroacetyl)prolyl choride in dichloromethane (1 M; Aldrich-Aldrich), sodium 
carbonate (Fischer Scientific, Fair Lawn, NJ), n-butyl chloride (Burdick & 
Jackson, Muskegon, MI) and acetonitrile (Mallinckrodt Inc, Paris, KT) were 
used. Piperidine deuterated dl-MPH·HCI was synthesized in-house[76] and 
contained approximately 25% of the Ds-isotopolog for SIM monitoring and 
containing no Do-1-MPH. It is noted that piperidine deuterated Dg-MPH·HCI is 
commercially available (Cerilliant). 
Animals 
Male C57 mice aged 8-10 weeks (25-35 g) were obtained from 
Jackson Laboratories (Bar Harbor, Maine, USA). They were individually 
housed in a temperature and humidity controlled colony room on a 12-h 
light/dark cycle (light: 07.00--19.00 h) with free access to food and water for at 
least 7 days before the start of any tests. All experiments were approved by 
and conducted within the guidelines of the Institutional Animal Care and Use 
Committee at the Medical University of South Carolina and followed the 
guidelines of the NIH Guide for the Care and Use of Laboratory Animals (NIH 
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Publication no. 80-23, revised 1996). Animal studies were conducted in the 
Institute of Psychiatry. 
Drug Administration 
Mice were randomly placed into 1 of 4 test groups as shown in Table 
1. All mice, regardless of group assignment, were treated similarly. This 
included the use of active (MTS) or placebo patches and delivery of ethanol 
or water by gastric intubation (gavage). To this end, mice were lightly 
anesthetized by placement into a chamber containing 5% isofluorane for 8-10 
min. The mice were removed and their hair was clipped along their abdomen 
and back, from shoulders to hips. 
Immediately after clipping hair, % of a 12.5 cm2 MPH transdermal patch, 
or a placebo patch (band-aid adhesive resembling the MTS), was applied to 
the lower left hip area. The patch was secured by applying tape over the 
patch and around the mouse for one full loop in order to ensure a constant 
skin interface and to prevent the mice from disturbing the patch. Mice were 
returned to their home cage for 15 min to recover from anesthesia, then 
dosed by gavage, according to their assigned group, i.e., 3.0 g/kg ethanol and 
7.5 mg/kg (calculated as the free base) dl-MPH·HCI, or deionized water 
(dH20) using a standard volume of 0.02 mUg body weight. 
Sample collection 
Following gavage, mice were individually placed for 3 h in single 
metabolic chambers designed to separate urine from solid waste. Urine was 
collected and measured to the nearest f,.IL. Mice were then deeply 
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anesthetized using isofluorane. Venous blood was collected using cardiac 
puncture and stored in heparinized tubes. The brain was removed, separated 
along the sagittal line, weighed, and stored as 2 separate samples. Used 
patches were collected and later extracted for residual dl-MPH to calculate 
the dose delivered to the cutaneous site. Blank urine, blood, and brain used 
for calibration curves were collected from mice not exposed to any drugs. All 
matrices were kept on dry ice until stored in a -70°C freezer. 
Sample Preparation 
Urine 
All urine samples were thawed immediately prior to analysis. Blank 
mouse urine (150 IJL) was fortified with dl-MPH over a range of 
concentrations (0, 0.5, 0.75, 1.5, 3,4.5 IJg/mL) and dl-EPH (0, 0.15, 0.3, 0.45, 
0.6, 0.9 1J9/mL) (Figure 3.4). These calibrators were run in parallel with 
experimental urine samples (150 IJL). The internal standard, piperidine 
deuterated dl-MPH, was dissolved in dH20 such that 200 IJL aliquots provided 
a concentration of 5 1J9 Ds-dl-MPH/1S0 IJL of urine. Sodium carbonate (SO IJL; 
1.2 M) was added to each urine sample to adjust the pH to approximately 9.5. 
Samples were extracted with n-butyl chloride: acetonitrile (2 mL; 4: 1) by 
vortexing for approximately O.S min. 
Blood 
All blood samples were thawed immediately prior to analysis and used 
in the freezer- hemolyzed state in view of MPH having previously been 
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reported to distribute nearly equally between serum and the red cell fraction 
[77]. Blank mouse blood (200 IJL) was fortified with dl-MPH over a range of 
concentrations (0, 0.05, 0.1, 0.25, 0.5, 0.75, 1.0 IJg/mL) and with dl-EPH (0, 
0.01, 0.025, 0.05, 0.075, 0.1 J..Ig/mL). These were run in parallel with 
experimental blood (200 IJL) as calibrators. The internal standard, piperidine 
deuterated dl-MPH, was dissolved in dH20 such that 200 J,JL aliquots provided 
a concentration of 5 IJg D5-dl-MPH/200 J..IL of blood. Sodium carbonate (2mL; 
1.2 M) was added to each blood sample to adjust the pH to approximately 
9.5. Samples were extracted with n-butyl chloride: acetonitrile (2 mL; 4:1) by 
vortexing for approximately 0.5 min. 
Brain 
All brain samples were thawed immediately prior to analysis. Blank 
mouse brain (1/2, left hemisphere) was fortified with dl-MPH over a range of 
concentrations (0, 0.025, 0.05, 0.1, 0.2, 0.5, 1.0, 1.5 tJg/g) and with dl-EPH (0, 
0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1.0 J..Ig/g) and run in parallel with experimental 
brains (left hemisphere). The internal standard, piperidine deuterated dl-MPH, 
was dissolved in dH20 such that 200 JJL aliquots provided a concentration of 5 
J..I9 D5-dl-MPH/150 J..IL of urine. The internal standard, piperidine deuterated dl-
MPH, was dissolved in dH20 such that 200 J..IL aliquots provided a 
concentration of 2.5 J,Jg D5-dl-MPHI brain sample. Sodium carbonate (2mL; 
1.2 M) was added to each brain sample to adjust the pH to approximately 9.5. 
Samples were homogenized (Polytron PT1200) for 10 sec, then 0.5 9 sodium 
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chloride was added and the samples were vortexed for 20 sec. Samples were 
extracted with n-butyl chloride: acetonitrile (2 mL; 4: 1) by vortexing for 30 sec, 
then centrifuged at 3000 rpm for 7 min. 
MPH extraction from used patches 
Used patches were analyzed for residual content of dl-MPH to 
establish the cutaneous dose delivered. Before being placed on the animal, 
whole patches (including the backing) were weighed and then cut into 
quarters. Each % was then weighed and used to determine what percent of 
the whole patch it represented. 
In advance of analyzing the used patches for their dl-MPH content, a 
method for dl-MPH recovery from unused patches was developed. The 
unused patches were placed in scintillation vials with methanol (1 
mL/calculated mg of dl-MPH) and sonicated over a range of times from 1 min 
to more than 20 min to determine the time required for near complete 
extraction/recovery. An unused 12.5 cm2 patch contains 27.5 mg of dl-MPH 
free base whereby a % patch contains 6.875 mg of dl-MPH. For specific % 
patch cuttings, the exact dl-MPH content was calculated as follows: (Weight 
of % MTS / Weight of whole MTS) x 27.5 = mg dl-MPH. Accordingly, for the 
used study patches, residual dl-MPH was determined by taking a 100 ~L 




The organic phases from all matrix extractions were transferred into 4 
mL screw-cap silanized vials (Supelco) and the solvent was evaporated to 
dryness under nitrogen. TFP-CI (1 M; 250 IJL) was added to each vial, sealed 
with Teflon® lined caps (Supelco) and heated at 58°C for 45 min. Aliquots of 
these samples were then transferred to silanized microvial inserts within auto 
sampler vials for GC-MS analysis. 
Instrumental analysis 
All analyses were conducted using an Agilent Model 6890 GC-5973N 
MS with ChemStation using a modification of published methods [41, 75]. GC 
separations were on a 30 m x 0.32 mm, 0.25 J..lm film thickness, 5% 
phenylmethylpolysiloxane fused-silica column (D8-5 J & W Scientific, Folsom, 
CA). Pulsed-splitless injections (2 JJL) were used. The injector port was fit with 
a deactivated glass wool protected sleeve operated at 250°C and the helium 
carrier gas linear velocity was 50 cm/s. The GC was held at 70° C for 1.5 min, 
then ramped to 315°C at 10° C/min and held for 4 min for a total run time of 
30 min. Detection was by EI ionization (70 eV) and SIM, acquiring the N-TFP-
piperidyl fragment ions of d-MPH, I-MPH, d-EPH and I-EPH (m/z 277) with D5-
d-MPH and D5-I-MPH monitored at m/z 282 (Figure 3.2). 
The lower limit of quantitation was based on a signal-to-noise ratio of 
~1 0 for all analytes. The signal-to-noise ratios for the lowest calibrators were 
~ 25. It is noted that calibrator concentrations are indicated as racemic (dl-) 
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MPH and EPH, while analyte concentrations are reported for each 
enantiomer. All calibration plots provided linearity of f2 > 0.99 (Figure 3.3). 
Statistical Methods 
A two way analysis of variance (ANOVA) followed by pair wise 
comparisons using the Student's t-test method was used in the analysis of all 
data. Samples were analyzed as independent samples and were assumed to 
have equal variances. Statistical analysis was conducted using SPSS 12.0 
(SPSS I.; Chicago, Illinois, USA). 
Results 
MPH dose delivered from MTS 
The dl-MPH dose received by the MTS test animals over the 3.25 h 
wear time was determined by extracting the remaining dl-MPH from used 
patches and back calculating from the initial dl-MPH content in a % of a 12.5 
cm2 MTS (Figure 3.4). Sonication for 15 min was necessary to extract a 
mean no less than 95% of the labeled dl-MPH content of unused % patches 
and, accordingly, 15 min of sonication was used to calculate the 3.25 h dose 
delivered by difference (Figure 3.5). Shorter sonication times did not allow for 
complete dl-MPH extraction, while using later time points caused the MTS 
matrix to significantly degrade. This resulted in the extractant becoming 
cloudy and GC-MS of such aliquots were found to foul the injector port and 
result in unacceptable chemical noise in the chromatograms. The mean dl-
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MPH dose delivered using the MTS over 3.25 h was 0.23 mg or 7.5 mg/kg. 
This dose was used for oral dosing (gastric intubation) in a parallel study of 
oral dl-MPH - ethanol interactions. The 7.5 mg/kg oral dose is likely to over-
represent the bioavailable fraction of the mean dl-MPH MTS dose calculated 
as above in view of the likelihood of some residual dl-MPH remaining in the 
skin prior to circulatory absorption, e.g., in humans dosed with MTS, residual 
dl-MPH results in a biphasic decay of the drug from plasma following patch 
removal [78]. 
Influence of ethanol on urinary analytes 
Transdermal dl-MPH 
The total urinary elimination of d-MPH following the 3.25 h MTS wear 
time was significantly greater in the animals dosed with ethanol compared to 
those given dH20 (Figure 3.6a; t = 5.52, df = 10, p<0.001); rising from 0.48 IJg 
to 1.39 1-19 to account for 0.04% of the total dose of d-MPH calculated to be 
cutaneously delivered. Further, in animals dosed with MTS, total urinary 
excretion of I-MPH was significantly increased, rising from 0.43 1-19 for animals 
dosed with dH20 to 0.96 JJg for animals dosed with ethanol (Figure 3.7a; t = 
4.07, df = 10, p<0.01). There was not a significant difference between the 
urinary excretion of d-MPH compared to I-MPH in animals dosed with dH20, 
however, in animals dosed with ethanol the urinary excretion of d-MPH was 
significantly greater than I-MPH (t = 2.13, df = 10, p<0.05). Both enantiomers 
of EPH were detectable in animals gavaged with ethanol, however, I-EPH 
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was enantioselectively formed with a significantly greater total elimination 
found relative to d-EPH (Figure 3.8a; t = 5.74, df = 10, p<0.001). The total 
urinary elimination of I-EPH was 0.2 ~g which represents 0.01 % of the total 
dose of I-MPH calculated to be cutaneously delivered, while the total urinary 
elimination of d-EPH was 0.05 ~g. The total urine volume excreted following 
ethanol treatment was significantly greater than following dH20 treatment (t = 
4.81, df = 10, p<0.001) as consistent with the diuretic effect of ethanol. 
Oraldl-MPH 
The total urinary elimination of d-MPH following oral dl-MPH over the 3 
h collection period was significantly greater in the animals dosed with ethanol 
compared to those given dH20 (Figure 3.6b; t = 7.56, df=10, p<0.001); rising 
from 0.09 ~g to 0.46 J,Jg and accounting for 0.0120/0 of the total dose of d-MPH 
gavaged. Further, in animals dosed with oral dl-MPH, the total urinary 
excretion of I-MPH was significantly increased, rising from 0.071-19 for animals 
dosed with dH20 to 0.31 ~g for animals dosed with ethanol (Figure 3.7b; t = 
5.45, df= 10, p<0.001). There was not a significant difference between the 
urinary excretion of d-MPH compared to I-MPH in animals dosed with dH20, 
however, in animals dosed with ethanol the urinary excretion of d-MPH was, 
significantly greater than I-MPH (t = 2.23, df = 10, p<0.05). Both isomers of 
EPH were detectable in animals gavaged with ethanol, however, I-EPH was 
enantioselectively formed with a significantly greater total urinary elimination 
of /-EPH relative to d-EPH (Figure 3.8b; t = 3.71, df = 10, p<O.01). The total 
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urinary elimination of /-EPH was 0.02 IJg, while the total urinary elimination of 
d-EPH was 0.005JJg. Again, the total urine volume excreted followed ethanol 
(a diuretic) treatment was significantly greater than following dH20 treatment (t 
= 4.39, df = 10, p<0.001). 
Influence of ethanol on blood analytes 
Transdermal dl-MPH 
The blood concentration of d-MPH after MTS dosing was significantly 
greater in animals dosed with ethanol compared with dH20; increasing 72% 
from 0.36 JJg/mL to 0.61 IJg/mL (Figure 3.6a; t = 4.22, df = 10, p<0.01 ),. 
Further, in animals dosed with MTS, concentrations of I-MPH significantly 
increased from 0.29 J,J9/mL for animals dosed with dH20 to 0.51 J,Jg/mL for 
animals dosed with ethanol (Figure 3.7a; t = 2.82, df = 10, p<0.05). There was 
no significant difference between the blood concentration of d-MPH and 1-
MPH in animals dosed with dH20 or in animals dosed with ethanol. Both 
enantiomers of EPH were formed in animals gavaged with ethanol, however, 
I-EPH was enantioselectively formed with a significantly greater concentration 
found relative to d-EPH (Figure 3.8a; t = 2.99, df = 10, p<0.05). The blood 
concentration of I-EPH was 0.04 IJg/mL, while the concentration of d-EPH 
was 0.03 J,Jg/mL. 
Oraldl-MPH 
The blood concentration of d ... MPH following oral dl-MPH was 
significantly greater in the animals dosed with ethanol compared to those 
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given dH20; increasing 59% from 0.018 IJg/mL to 0.03 IJg/mL (Figure 3.6b; t = 
2.95, df = 10, p<0.05). Further, in animals dosed with oral dl-MPH, 
concentrations of I-MPH were significantly increased from 0.015 1J9/mL for 
animals dosed with dH20 to 0.05 IJg/mL for animals dosed with ethanol 
(Figure 3.7b; t = 4.56, df = 10, p<0.001). There were no significant differences 
between the blood concentration of d-MPH and I-MPH in animals dosed with 
dH20 or in animals dosed with ethanol. Neither isomer of EPH was detectable 
in animals gavaged with oral dl-MPH and ethanol. 
Effect of ethanol on brain analytes 
Transdermal dl-MPH 
The brain concentration of d-MPH after MTS dosing was significantly 
greater in animals dosed with ethanol compared the dH20 group; increasing 
65.3%from 0.81 1J9/9 to 1.34 IJg/g (Figure 3.6a; t = 2.89, df =10, p<O.05). 
Further, in animals dosed with MTS, concentrations of I-MPH were 
significantly increased by ethanol, rising from 0.84 1J9/9 for animals dosed 
with dH20 to 1.33 1J9/g for animals dosed with ethanol (Figure 3.7a; t = 2.18, 
df =10, p<O.05). There were no significant differences between the brain 
concentration of d-MPH and I-MPH in animals dosed with dH20, or in animals 
dosed with ethanol. Both isomers of EPH were formed in animals gavaged 
with ethanol, however, I-EPH was enantioselectively formed with a 
significantly greater concentration found relative to d-EPH (Figure 3.8a; t = 
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8.57, df = 10, p<O.001). The brain concentration of I-EPH was 0.14 J.J9/g, 
while that of d-EPH was 0.005 IJg/g. 
Oraldl-MPH 
The brain concentration of d-MPH following oral dl-MPH was 
significantly greater in the animals dosed with ethanol compared to those 
given dH20; increasing 40.60/0 from 0.03 J.Jg/g to 0.05 J.Jg/g (Figure 3.6b; t = 
3.67, df = 10, p<0.01). Further, in animals dosed with oral dl-MPH, 
concentrations of I-MPH were significantly increased from 0.02 IJg/g for 
animals dosed with dH20 to 0.06 J.j9/9 for animals dosed with ethanol (Figure 
3.7b; t = 3.83, df = 10, p<0.01). There were no significant differences between 
the brain concentration of d-MPH and I-MPH in animals dosed with dH20 or in 
animals dosed with ·ethanol. Both isomers of EPH were formed in animals 
gavaged with ethanol; however, I-EPH appeared to have been 
enantioselectively formed, though the mean concentration was not 
significantly different from that of d-EPH (Figure 3.8b). 
Discussion 
Oral dl-MPH in humans is subject to pronounced enantioselective first-
pass metabolism which limits I-isomer systemic exposure to approximately 
1 % that of d-MPH [28]. The mean absolute bioavailability of dl-MPH has been 
reported to be 300/0, but ranges from 11-51 % [79-80]. In effect, first-pass 
metabolism biocatalytically "resolves" oral dl-MPH [81], resulting in only the d-
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isomer appreciably reaching the bloodstream. The d-isomer component of dl-
MPH is generally regarded as the pharmacologically active isomer, 
responsible for efficacy in the treatment of ADHD [82-83]. The low oral 
bioavailability of dl-MPH is largely due to the facile hydrolysis of the 
constituent methyl ester to yield the inactive [24] metabolite dl-ritalinic acid 
and catalyzed primarily through the actions of CES1 [37-39, 84]. This facile 
pathway limits the half-life of dl-MPH to only 2-3 h [85]. Approximately 1 % of 
MPH is excreted in urine unchanged in humans over 24 h, and excreted 
predominantly as the d-isomer [75]. 
Our studies with mice dosed with oral dl-MPH (7.5 mg/kg) and dH20, 
while being limited to a single 3 h time point for blood and brain sampling, 
suggest a lower degree of metabolic enantioselectivity relative to humans. 
whereby the d-MPH-to-I-MPH ratio for blood and brain were 1.22 and 1.36, 
respectively. This apparent greater oral bioavailability of I-MPH in the C57 
mouse than in man is in general agreement with plasma results using CD1 
mice dosed at 5.0 mg/kg [86] or pregnant rats dosed at 7.0 mg/kg [87] . 
Further, the extent of accumulation in brain relative to blood will be expected 
to be less dramatic at 3 h than at earlier time points, especially after oral 
administration were the decay time course to resemble that of the Sprague-
Dawley rat [77]. 
A primary aim of the present study was to model transdermal MPH -
ethanol metabolic interactions. A quarter of the smallest commercially 
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available MTS patch was used and this delivered a mean dose of 
approximately 7.5 mg/kg of dl-MPH over the 3.25 h wear period based on the 
difference between drug content before and after application. Though the 
MTS is not designed to be cut into portions for clinical applications, the dl-
MPH content in each patch is evenly distributed throughout the patch [16] and 
required apportioning when using such a small species as the mouse. dl-MPH 
delivery has been reported to occur in a manner directly proportional to the 
patch surface area in humans [16, 88]. Accordingly, the drug content in the % 
12.5cm2 patches used in the present study was 250/0 of 27.5 mg, i.e., 6.88 
mg. The mean dose of 0.23 mg of dl-MPH delivered to the mice (n = 12) over 
the 3.25 h wear represents 3.3% of the % patch content of dl-MPH and 
ranged from 1.9 - 5.1 %. In humans, the uncut 12.5 cm2 patch size is designed 
to deliver a mean dl-MPH dose of 10 mg over the recommended 9 h wear. 
This dose represents 36% of the patch dl-MPH content, though ranging 
between subjects from 15-72% [89]. 
These apparent transdermal dl-MPH absorption differences reflect 
many factors including: (1) the shorter wear time of 3.25 h for the mouse, (2) 
the faster rate of ester substrate metabolism expected with rodents relative to 
humans [90], (3) the hair follicle rich shaved skin of the mice opposed to the 
skin surface of the recommended hip placement in clinical applications, and 
(4) the potential for a greater relative absorption lag time for the 3.25 h wear 
versus 9 h in humans. In this latter context, the average lag time for 
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detectable d-MPH in plasma after applying MTS to humans is 3.1 h (ranging 
from 1-6 h) [91]. The above factors notwithstanding, it is recognized that the 
percutaneous absorption rate for a range of drugs in mice and other rodents 
has generally been found to be more rapid than in humans or pigs [92]. 
While the present investigation appears to represent the first MTS 
study to use mice, previous preclinical studies have shown that shaved mice 
serve to model transdermal drug delivery [93]. Hairless or nude mice are 
more typically used for transdermal delivery studies across the range of patch 
technologies [94], however, the neuropharmacological reference strain status 
of the C57 mouse provided the justification for its use in investigating dl-MPH 
- ethanol interactions (see Introduction). Maintaining the mice in the 
metabolic chambers for a total of 3 h allowed for the collection of adequate 
urine volume for analysis, while still permitting quantification of analytes from 
blood and brain. In this context, the mean elimination half-life of dl-MPH in 
mice (B6C3F1 strain; 3 mg/kg p.o.) has been reported to be 1.1 h [95], while 
that of ethanol (2 g/kg i.p.) in C57 mice appears to be approximately 1.3 h 
[96]. 
Enantiose/ective I-EPH transesterification 
As with oral dosing in humans [27], coadministration of ethanol and 
transdermal or oral dl-MPH in C57 mice resulted in the enantioselective 
transesterification of dl-MPH, favoring I-MPH over d-MPH as a substrate. 
EPH was detectable in the brain, blood and urine of these mice. Selection of 
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an appropriate species to model esterase-mediated metabolism of dl-MPH 
was an important consideration in our study design. For instance, beagle 
dogs have been used in pioneering dl-MPH metabolism studies [97], and in 
subsequent toxicokinetic studies [98]. However, esterase-mediated hydrolysis 
of dl-MPH in beagle dogs exhibit the opposite enantioselectivity, preferentially 
deesterifying d-MPH over I-MPH [99]. Further, based on both human 
investigations [27], and the present findings with C57 mice, the 
enantioselective formation of I-EPH with co-administration of dl-MPH and 
ethanol is accompanied by an elevation in d-MPH concentrations relative to 
dosing with dl-MPH alone. While I-EPH formation was found to be 
enantioselective, this metabolic pathway was not enantiospecific, i.e., I-EPH 
concentrations significantly exceededd-EPH values though d-EPH was 
readily detectable and quantifiable in C57 mouse samples following MTS and 
ethanol, as well as in the urine of animals dosed orally with dl-MPH. In 
humans dosed orally with dl-MPH and ethanol, d-EPH rarely exceeded 100/0 
of the concentration of I-EPH [27]. 
In potential forensic medicine applications [72], detection of EPH from 
biological samples could serve as a biomarker to demonstrate combined 
consumption of dl-MPH and ethanol; analogous to the detection of 
cocaethylene as evidence of cocaine - ethanol coabuse [100]. 
The high degree of hepatic localization of CES1 compared to its low 
level of intestinal expression implicates hepatic transesterification as the 
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primary site of EPH formation after oral dosing of dl-MPH [38]. However, 
when dosing dl-MPH by the transdermal route, presystemic esterase 
metabolism may also occur, as has been reported during percutaneous 
disposition of ester containing drugs. Transdermal presystemic hydrolysis has 
been especially associated with the cutaneous fat layer, where methyl ester 
and ethyl ester containing drugs are reported to be readily deesterified in skin 
during transdermal transport [92,101-104]. Some degree of presystemic 
transesterification of dl-MPH to EPH may also occur. In the presence of 
ethanol, transesterification of methyl esters to ethyl esters has been reported 
in skin [105]. For instance, the methyl ester methylparaben is rapidly 
hydrolyzed in skin [102], though in the presence of ethanol hydrolysis of 
methylparaben is inhibited by competitive esterase-mediated 
transesterification of methylparaben to ethylparaben in pig [106] or human 
[107] skin. 
As with hepatic esterase substrates, skin esterase activity has also 
been reported to exhibit enantioselectively, e.g., during prodrug ester 
activation by hydrolysis [108]. The possibility of cutaneous esterase-mediated 
biotransformation resulting in transesterification of transdermal dl-MPH with 
ethanol may be favored by the mildly basic cutaneous pH expected at the 
MTS application site considering the high concentration of dl-MPH free base 
found in MTS [16]. Mild cutaneous basicity has been reported to accelerate 
the rate of ester xenobiotic hydrolysis. For instance, esterase activity toward 
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transdermal drug substrates was accelerated at a pH of 8, but was inhibited 
at the lower pH of 5 [107]. dl-MPH is an especially weak organic base even 
though it contains a secondary aliphatic amine; it exhibits a pKa of 8.4 versus 
the pKa of 9.6 for the stimulant methamphetamine [109]. This relatively low 
basicity of dl-MPH has been theorized to be a consequence of an 
intramolecular hydrogen bonding interaction between the amine and the 
methyl ester carbonyl within the MPH structure [110]. 
Still considering the potential for some degree of cutaneous EPH 
formation, in addition to subsequent hepatic metabolism, oral ethanol is 
rapidly distributed throughout mammalian tissue, and a portion of the non-
metabolized dose is excreted cutaneously (sweat), in addition to ethanol 
excretion by the lungs and kidney [111]. Finally, even oral MPH reaches skin, 
as demonstrated using commercial sweat patches placed on the back [112]. 
Significant increases in d-MPH concentrations by ethanol 
The concentrations of d-MPH in blood, brain and urine were 
significantly greater in mice dosed with ethanol than those dosed with dH20. 
These findings occurred when dosing either transdermally or orally. d-MPH 
elevation following concomitant MPH-ethanol administration was especially 
pronounced under the conditions used when dosing dl-MPH by the 
transdermal route. However, any direct comparisons between the extent to 
which ethanol influences either d-MPH concentrations or EPH formation as a 
function of dosing route cannot be reasonably made due to the inherent 
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disparities of comparing an oral bolus dose of dl-MPH with that of the ongoing 
release of dl-MPH from the MTS. It is possible that the elevated I-MPH levels 
associated with transdermal dosing in C57 mice relative to oral dosing could 
be relevant to the extent to which ethanol elevates d-MPH in the course of 
ethanol interacting with CES1 to form I-EPH. 
Approximately 50 times more of I-MPH reaches the systemic 
circulation in humans when dl-MPH is dosed transdermally than when dosed 
orally [29], and I-MPH is the isomer which enantioselectively serves as a 
CES1 substrate in the presence of ethanol [27, 38-39, 113-114]. Were 
ethanol to facilitate d-MPH absorption from the MTS through esterase 
,inhibition at the level of the skin and/or liver, the resulting higher drug 
concentrations, and potentially more rapid rate of absorption of MPH, may 
influence pleasurable effects [27] of this drug combination, and contribute to 
additional abuse liability [47-49]. Further, elevated d-MPH plasma 
concentrations pose the potential for adverse or lethal [72] cardiovascular 
effects [42-43]. In view of the significant influence of ethanol on d-MPH 
concentrations in the C57 mouse model reported here, transdermal dl-MPH 
used to treat adult ADHD may be associated with clinical considerations 
unique to this route of administration, should drug interaction findings from of 




Enantioselective transesterification of dl-MPH to I-EPH following concomitant 
ethanol. 
Figure 3.2 
Representative GC-MS-SIM chromatogram of d-MPH, I-MPH and I-EPH from 
a C57 mouse brain extract (upper ion profile). The sample was collected 3.25 
h after dosing with % of a 12.5 cm2 MTS and 3 h after dosing with 3.0 g/kg 
ethanol by gavage. Enantiospecific analysis used chiral derivatization and a 
deuterated internal standard (lower ion profile). 
Figure 3.3 
Calibration plots of spiked mouse urine were used to determine 
concentrations of MPH and EPH in experimental samples. AliI> 0.99. 
Figure 3.4 
Residual MPH from used X 12 cm2 patches established transdermal dose 
delivered. 
Figure 3.5 
Extraction efficiency of unused % 12 cm2 dl-MPH transdermal patches. 
Figure 3.6 
(A) In mice treated with X of a 12.5 cm2 MTS for 3.25 h, ethanol (3.0 g/kg, 
gavaged at 0.25 h) increased total excretion of d-MPH in urine and increased 
d-MPH concentrations in blood and brain relative to dH20. 
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(8) In mice gavaged with dl-MPH (7.5 mg/kg), concomitant ethanol (3.0 g/kg) 
increased total 3 h urinary excretion of d-MPH, and increased 3 hd-MPH 
concentrations in blood and brain, relative to gavage dosing with dl-MPH (7.5 
mg/kg) and dH20. *, P < 0.05; **, P < 0.01; ***, p < 0.001. 
Figure 3.7 
(A) In mice treated with % of a 12.5 cm2 MTS for 3.25 h, ethanol (3.0 g/kg, 
gavage at 0.25 h) increased total excretion of I-MPH in urine and increased /-
MPH concentrations in blood and brain relative to dH20 gavage. 
(8) In mice gavaged with dl-MPH (7.5 mg/kg), concomitant ethanol (3.0 g/kg) 
increased total 3 h urinary excretion of d-MPH, and increased 3 hi-MPH 
concentrations in blood and brain, relative to gavage dosing with dl-MPH (7.5 
mg/kg) and dH20. *, P < 0.05; **, P < 0.01; ***, p < 0.001. 
Figure 3.8 
(A) Ethanol (3.0 g/kg, gavage at 0.25 h) and % of a 12.5 cm2 MTS resulted in 
enantioselective /-EPH formation as quantified in 3.25 h urine, blood and 
brain. 
(8) Concomitant gavage of ethanol (3.0 g/kg) and dl-MPH (7.5 mg/kg) 
resulted in greater 3 h urinary elimination of I-EPH than for d-EPH. EPH was 
not detectable (ND) in 3 h blood using dosing regimen. In brain, the mean 1-
EPH concentration was greater, but not significantly (NS) different from that of 
d-EPH. EPH offers the potential of serving as a biomarker for combined dl-
MPH - ethanol exposure. *, p < 0.05; **, P < 0.01; ***, p < 0.001. 
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Oral and transdermal dl-methylphenidate - ethanol interactions in 
C57BU6J mice: Potentiation of locomotor activity with oral delivery 
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Introduction 
The persistent of ADHD into adulthood has been increasingly 
recognized over the past few decades [4-5]. In a survey, 920/0 of adult ADHD 
patients prescribed dl-MPH reported concomitant use of ethanol. Further, 
1000k of individuals who obtained dl-MPH through diversion co-abused 
ethanol [18]. The abuse potential of the dl-MPH - ethanol combination is well 
known in the clinical literature [32-34]. 
Coadministration of dl-MPH and ethanol results in pharmacokinetic 
and pharmacodynamic drug - drug interactions in humans [27] and in C57 
(C57) mice [46, 115]. Ethanol elevates biological concentrations of the 
pharmacologically active d-MPH isomer and yields the metabolic 
transesterification product EPH [27, 115]. EPH appears to be formed through 
the actions of carboxylesterase 1 (CES1) [27,71] which exhibits I-MPH 
substrate enantioselectivity in both the metabolic transesterification and 
deesterification pathways [37, 39-40] (Figure 4.1). Accordingly, the mean 
absolute oral bioavailability of I-MPH is limited to only 1-30/0 compared to 
approximately 30% for d-MPH [80]. However, dosing with transdermal dl-
MPH (Daytrana~ avoids the extensive oral presystemic metabolism and 
leads to approximately 50 times more I-MPH reaching the systemic circulation 
when compared with oral dosing [16]. 
The pharmacological significance of dosing route dependent 
alterations in the relative bioavailability of d-MPH versus I-MPH was 
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investigated in the present study using a C57 mouse model in the context of 
ethanol interactions. The C57 mouse has served as a common reference 
strain in pre-clinical investigations of psychotropic agents, including the study 
of dl-MPH - ethanol interactions [40, 46, 115], as well as for the behavioral 
characterization of EPH enantiomers [40-41]. As with humans, C57 mice 
enantioselectively transesterify I-MPH to I-EPH [40, 115] (Figure 4.1) as well 
as exhibit a biphasic excitatory-to-depressant activity profile in response to 
increasing doses of ethanol [116]. 
A relatively low intraperitoneal (i.p.) dose of ethanol (1.75 g/kg) has 
been shown to elevate motor activity for 10-15 min in C57 mice [46]. 
However, when this dose of ethanol was combined with a sub-stimulatory 
dose of dl-MPH (1.25 mg/kg, Lp.), a potentiation of ethanol induced motor 
activity occurs. As an extension of this low dose dl-MPH - ethanol behavioral 
study [46], and a C57 mouse dispositional investigation where ethanol was 
found to elevate blood, brain and urinary d-MPH [115] , the following 
investigation examined the pharmacology of a high, otherwise motor 
depressive dose of ethanol, combined with a high stimulant dose of oral or 
transdermal dl-MPH. Locomotor activity counts were acquired for 3 h followed 
by enantiospecific MPH and EPH brain analysis. 
The influence of ethanol on the stimulant effects of dl-MPH carries 
special abuse potential and adverse event liability for patients prescribed dl-
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MPH to treat ADHD, as well as for individuals obtaining dl-MPH through 
diversion. 
Materials and Methods 
Materials 
Ethanol was from AAPER Alcohol and Chemical Co. (Shelbyville, KY; 
95%). dl-MPH·HCI used for oral animal studies was from Sigma-Aldrich (St. 
Louis, MO; lot # 118K1052) and 12.5 cm2 transdermal dl-MPH patches 
(Daytrana~ were from Shire US (VVayne, PA; lot # 2616811; smallest of 4 
sizes available). Laboratory tape used to secure transdermal dl-MPH or 
placebo patch (cut Band-Aid® adhesive which closely resembles the texture, 
adhesion and thickness of the dl-MPH patch) was from "W-JR International 
(white, 12.7 mm). dl-MPH·HCI in methanol (1 mg/mL calculated as free base; 
Cerilliant, Round Rock, TX) and dl-EPH·HCI in ethanol (1 mg/mL calculated 
as free base, synthesized in-house [41]) were used as the analytical 
reference standards. Sodium carbonate (Fischer Scientific, Fair Lawn, NJ), n-
butyl chloride (Burdick & Jackson, Muskegon, MI), acetonitrile (Mallinckrodt 
Inc, Paris, KT), (S)-N-(trifluoroacetyl)prolyl choride in dichloromethane (1 M; 
Sigma- Aldrich, St Louis, MO), were used for extraction and chiral 
derivatization. Piperidine deuterated dl-MPH·HCI was synthesized in-house 
[76] and contained approximately 250/0 of the D5-isotopolog for SIM 
monitoring and containing no DO-1-MPH. 
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Animals 
Male C57 mice aged 8-10 weeks (25-35 g) were obtained from 
Jackson Laboratories (Bar Harbor, Maine, USA). They were individually 
housed in a temperature and humidity controlled colony room on a 12 h 
light/dark cycle (light: 07.00-19.00 h) with free access to food and water. All 
experiments were approved by and conducted within the guidelines of the 
Institutional Animal Care and Use Committee at the Medical University of 
South Carolina and followed the guidelines of the NIH Guide for the Care and 
Use of Laboratory Animals (NIH Publication no. 80-23, revised 1996). 
Locomotor Activity and Analysis 
Apparatus 
Motor activity was assessed with a Digiscan Animal Activity Monitor 
system, model RXYZCM(8) TAO with a two-animal option (Omnitech 
Electronics, Columbus,Ohio, USA). Each activity chamber contained 2 arrays 
of 16 photo beams spaced 5 cm apart, with eight beams located on the x-axis 
and eight on the y-axis. One array was located 1.5 cm above floor level to 
capture horizontal activity and the other was located 6.5 cm above the floor to 
capture vertical activity of the mice. Stereotypic counts were recorded when 
the same beam was repeatedly interrupted. Photocells were activated when 
the photo beams on the wall directly opposite to the cells were interrupted. 
The Versadat analyzer (Version 2.70-137E) recorded the interruption of each 
beam and provided the total distance (cm) and vertical activity for each 
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animal during testing. Each activity chamber was partitioned into 20 x 20 cm 
quadrants with acrylic dividers to allow simultaneous testing of two mice. 
Four activity chambers allowed testing of eight mice per session. Each of the 
activity chambers were enclosed in 90 x 54 x 35 cm sound-attenuated boxes. 
Procedures for locomotor activity assessment 
On days 1-3, mice were habituated to the motor activity apparatus for 
30 min. On day 4 mice were lightly anesthetized with 5% isofluorane for 8-10 
min. The hair was clipped with an electric shaver along the abdomen and 
back, from shoulders to hips. A placebo patch was placed on the lower left 
hip and secured by laboratory tape over the patch and around the mouse for 
one full loop to ensure a constant skin interface and to prevent the mice from 
disturbing the patch. Mice were then gavaged at a volume of 0.02 mUg body 
weight with deionized water (dH20) and placed in the open-field activity 
chambers for 3 h. On Day 5, mice were randomly placed into 1 of 6 test 
groups (all with n = 8): placebo patch + dH20, placebo patch + ethanol, 
placebo patch + oral dl-MPH + dH20, placebo patch + oral dl-MPH + ethanol, 
transdermal dl-MPH + dH20, or transdermal dl-MPH + ethanol. Oral dl-MPH 
was dosed as the Hel salt using 7.5 mg/kg calculated as the free base. This 
dose was the mean dose absorbed by ~ patch as established by drug load 
difference between an unused versus used mouse patch study [115]. Each 
animal was anesthetized and either a placebo patch or % of 12 cm2 
transdermal patch was placed around the midsection in the same manner as 
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day 4. They were gavaged at a volume of 0.02 mUg body weight with either 
dH20 or ethanol (3.0 g/kg) and placed in the activity apparatus for 3 h. 
Following the conclusion of the locomotor activity session, animals were 
sacrificed and brain samples collected. 
The order of treatment groups within each week, and the particular test 
chamber used to test the different groups was counterbalanced across the 
entire experiment to eliminate any contribution of possible differences in 
activity monitors or days of testing to observed effects on motor activity. Total 
distance and vertical activity were recorded in 5-min bins for the entire 3 h 
session. 
Locomotor Activity Data Analysis 
Locomotor activity data in Figures 4.2 and 4.3 was grouped into 20 
bins and analyzed using a mixed factor three-way analysis of variance 
(ANOVA). Oral dl-MPH data and transdermal dl-MPH data were analyzed 
separately using a 2(dl-MPH dose) X 2(ethanol dose) X 9(TimeBin) design. 
The between groups factors are dl-MPH (dH20 vs. active dose) and ethanol 
(dH20 vs. active dose). The repeated measure is TimeBin. When 
appropriate, post-hoc comparisons of significant main effects or factor 
interactions were made using pair-wise comparisons with Bonferroni's 
correction. Statistical analysis was conducted using PASW Statistics 18 
(SPSS Inc., Chicago, Illinois, USA). 
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Brain MPH and EPH analysis 
Enantiospecific analysis of d-, I-MPH and d-, I-EPH was conducted as 
previously described in a recent dl-MPH - ethanol disposition report [115] . 
Briefly, homogenized and alkalinized 1/2 brains were solvent extracted and 
after chiral derivatization, the samples were injected into a gas 
chromatograph - mass spectrometer fit with a 5% phenylmethylpolysiloxane 
column. The trifluoroprolylpiperidyl electron impact fragment ions from 
analytes and the deuterated dl-MPH internal standard were acquired using 
selected ion monitoring. A range of spiked blank brain calibrators bracketed 
all concentrations reported as established by linear regression analysis (~ > 
0.99). 
Brain Concentration Data Analysis 
A two way analysis of variance (ANOVA) followed by pair wise 
comparisons using the Student's t-test method was used in the analysis of all 
data. Samples were analyzed as independent samples and were assumed to 
have equal variances. Statistical analysis was conducted using SPSS 12.0 
(SPSS I.; Chicago, Illinois, USA). 
Results 
Controls 
Mice treated with placebo patches + ethanol (3.0 g/kg) showed 
Significantly less total distance traveled compared to mice treated with 
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placebo patch + dH20 over the first 100 min (all ps<O.05) and significantly less 
vertical activity for the entire 3 h (all ps<O.01). 
Total Distance Traveled 
Oraldl-MPH 
The total distance traveled data was analyzed by examining changes 
in horizontal activity across time for the different treatment groups and is 
summarized in Figure 4.2A. A significant 3 way interaction was found 
(F(8,224)= 10.906, P <0.001). Post-hoc analysis indicated a significant 
increase in total distance traveled for oral dl-MPH + dH20 compared to the 
placebo patch + dH20 for the first 1 h (all ps<O.05). Further, total distance 
traveled for the oral dl-MPH + ethanol group was significantly greater than 
oral dl-MPH + dH20 group over the first 100 min (all ps<O.5). 
Transdermal dl-MPH 
The total distance traveled data was analyzed by examining changes 
in horizontal activity across time for the different treatment groups and are 
summarized in Figure 4.3A. The 3 way interaction was not significant for the 
transdermal dl-MPH group. However, the lower level 2 way interactions were 
significant for TimeBin vs. ethanol (F(8,224)=5.27, p<O.001) and TimeBin vs. 
dl-MPH (F(8,224)=28.07, p<O.001). Post hoc analysis indicated a significant 
increase in total distance traveled for the transdermal dl-MPH + dH20 group 
compared to the placebo patch + dH20 group over the 100-180 min time 




The vertical activity data was analyzed by examining changes in 
activity across time for the different treatment groups and is summarized in 
Figure 4.2B. A significant 3 way interaction was found (F(8,224)=207.747, p 
<0.001). Post-hoc analysis indicated a significant increase in vertical activity 
for oral dl-MPH + dH20 compared to the placebo patch + dH20 for the first 100 
min (all ps<O.05). Vertical activity data for mice dosed with oral dl-MPH + 
ethanol and mice dosed with placebo patch + ethanol were significantly 
decreased compared to the placebo patch + dH20 and oral dl-MPH + dH20 for 
the entire 3 h (all ps<0.001). 
Transdermal dl-MPH 
The vertical activity data was analyzed by examining changes in activity 
across time for the different treatment groups and is summarized in Figure 
4.38. A significant 3 way interaction was found (F(8,224)=34.935, p <0.001). 
Post-hoc analysis indicated a significant increase in vertical activity for 
transdermal dl-MPH + dH20 compared to the placebo patch + dH20 100-180 
min (all ps<O.01). Vertical activity data for mice dosed with transdermal dl-
MPH + ethanol and mice treated with placebo patch + ethanol were 
significantly decreased compared to placebo the patch + dH20 and 
transdermal dl-MPH + dH20 groups for the entire 3 h (all ps<O.001). 
Brain Drug and Metabolite Concentrations 
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Oraldl-MPH 
The brain concentration of d-MPH following oral dl-MPH was 
significantly greater in the animals dosed with ethanol compared to those 
given dH20; increasing from 31 ng/g to 51 ng/g (Figure 4.4A; t = 3.92, df = 14, 
p<O.001). Further, in animals dosed with oral dl-MPH, concentrations of 1-
MPH were significantly increased from 33 ng/g for animals dosed with dH20 to 
42 ng/g for animals dosed with concomitant ethanol (Figure 4.4A; t = 2.24, df 
= 14, p<O.05). There were no significant differences between the brain 
concentrations of d-MPH and I-MPH in animals dosed with dH20 or in animals 
dosed with ethanol. Only the I-isomer of EPH was detected in animals 
gavaged with ethanol and was found at a concentration of 10 ng/g (Figure 
4.4A). 
Transdermal dl-MPH 
The brain concentration of d-MPH after transdermal dosing was 
significantly greater in animals dosed with ethanol compared the dH20 group; 
increasing from 689 ng/g to 1,294 ng/g (Figure 4.48; t = 7.38, df =14, 
p<O.001). Further, in animals dosed with transdermal dl-MPH, concentrations 
of I-MPH were significantly increased by ethanol, rising from 685 ng/g for 
animals dosed with dH20 to 1,210 ng/g for animals dosed with ethanol (Figure 
4.48; t = 7.689, df =14, p<O.001). There were no significant differences 
between the brain concentration of d-MPH and I-MPH in animals dosed with 
dH20, nor in animals dosed with ethanol. Only the I-isomer of EPH was 
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detected in animals gavaged with ethanol and was found at a mean 
concentration of 130 nglg (Figure 4.48). 
Discussion 
Most oral dl-MPH abusers coabuse ethanol [18] and the abuse potential of 
the dl-MPH - ethanol combination is well known in the clinical literature [32-
34]. In the present study, C57 mice were used to model pharmacological 
characteristics of this drug combination to gain insight into the special appeal 
this drug combination has. The abuse potential of the new transdermal dl-
MPH formulation has not been investigated in detail at this time. In industry 
trials, transdermal dl-MPH been has reported to produce mild euphoria upon 
application of 3 or 6 of the 25 cm2 patches. With the 6-patch application group 
dysphoria was reported in 42% of the test subjects. It is noted that the FDA 
requested human testing by the contraindicated application of the patch to 
buccal mucosa. This tissue surface greatly accelerated dl-MPH absorption 
relative to the normal hip application. Rather than the mean 36% of the patch 
dl-MPH content being absorbed during the recommended 9 h wear, 50% was 
absorbed in 2 h attached in the mouth (see Patrick et al. 2009). 
We have previously reported that a sub-stimulatory Lp. dose of dl-MPH in 
C57 mice potentiates the motor stimulation produced by a low dose of ethanol 
[46]. The present study used stimulatory oral or transdermal doses of dl-MPH 
(7.5 mg/kg), with or without a depressive dose of ethanol (3 g/kg) to model 
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dosing route dependent behavioral and dispositional drug interactions as may 
pertain to both the treatment of adult ADHD patients who use or abuse 
ethanol and the co-abuse pharmacology of diverted dl-MPH and ethanol. 
The findings in the present study demonstrate that even a depressive dose 
of ethanol potentiates a stimulatory dose of oral dl-MPH. This potentiation 
may result from both pharmacokinetic and pharmacodynamic interactions. 
The 7.5 mg/kg doses of dl-MPH used in the present study approaches the 
highest daily doses found in the medical drug abuse literature, e.g., 
approximately 10 mg/kg/day intranasally [117] or 29 mg/kg/day intravenously 
[118] based on 70 kg total body weight (actual weights were not reported). 
While these doses were reported as total daily doses and the dosing 
"regimen" undisclosed, the intranasal route and certainly the intravenous 
routes are expected to result in higher bioavailability than following oral 
dosing. For instance, only 19% of an oral dl-MPH dose reaches the systemic 
circulation in rats [119] versus approximately 300/0 in humans [79]. Further, a 
transdermal dose of dl-MPH is absorbed in a prolonged fashion analogous to 
a multiple dose regimen as the abusers above were likely to have used. 
The ethanol dose of 3 g/kg used in this study corresponds to 10 ounces of 
80% vodka in a 70 kg human, well within the range of ethanol consumption 
associated with bingeing. The choice of a 3 g/kg dose allowed comparisons 
with the urinary metabolites, blood and brain concentrations of dl-MPH and 
dl-EPH found in the previous metabolism study [115]. Further, this dose 
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allowed us to indirectly gauge probable concentrations of ethanol over the 
course of the present behavioral studies through comparison with literature 
values in C57 mice. Haseba et al. (2007) found the peak ethanol 
concentration to be 322 mg% at 0.5 h, declining to approximately 35 mg% 3 h 
after oral dosing. 
Ethanol has been shown to significantly increase the maximum plasma 
concentration and total exposure to d-MPH and I-MPH in humans [27], as well 
as elevate d-MPH and I-MPH blood, brain and urine concentrations in the 
C57 mouse [115]. The present brain d-MPH, I-MPH and I-EPH 
determinations are concordant with our earlier reported brain concentrations 
[115]. At the 3 h sacrifice time, the mean d-MPH brain concentration was 23 
times higher in the transdermal group than in the oral dosing group without 
ethanol. Upon co-administration of ethanol, there was an 880/0 elevation of d-
MPH in the transdermal group and 660/0 elevation following oral dl-MPH at the 
3 h time point. 
At the pharmacodynamic level, the potentiation of dl-MPH induced 
behavioral effects may be based on the mutual influence of these drugs on 
dopamine, i.e., both d-MPH and ethanol have been reported to elevate 
synaptic dopamine levels. The therapeutic activity of the stimulant dl-MPH in 
the treatment of ADHD prominently involves the reuptake blockade of impulse 
released dopamine through binding to the dopamine transporter [120]. In our 
animal model of dl-MPH - ethanol co-abuse, the potentiation of stimulatory 
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effects by concomitant ethanol is consistent with evidence that ethanol 
releases pre-synaptic dopamine [121-122] as a consequence of upstream 
GABAergic signaling [123]. Hence ethanol may be increasing extracellular 
dopamine release, whereby d-MPH then blocks a larger dopamine pool from 
presynaptic reuptake. Further, ethanol-mediated dopamine release 
significantly increases as the ethanol dose (i.p.) is escalated from 1 g/kg to 2 
g/kg to 3 g/kg in C57 mice [122]; the 3 g/kg of ethanol corresponding to the 
oral dose used in the present study_ In this context, we hypothesize that the 
increased locomotor activity resulting from concomitant oral dl-MPH and an 
otherwise depressive dose of ethanol may reflect a synergistic increase in 
synaptic dopamine, modeling the accentuation of likeability associated with 
dl-MPH combined with ethanol when compared to dl-MPH alone [27]. 
In humans, the earliest detection of either MPH isomer in plasma after 
transdermal dl-MPH application ranges from 1-6 h [91], unlike oral dl-MPH 
which is readily detectable within 30 min or less [124-125]. The significantly 
lower total distance traveled of mice dosed with transdermal dl-MPH 
compared to oral dl-MPH is likely influenced by a lag phase (latency) in 
transdermal drug absorption during which time locomotor activity of mice 
inherently decreases as habituation to the activity chamber occurs. We report 
here that the lag phase between application of the transdermal dl-MPH patch 
and the onset of pronounced drug-induced motor activity is approximately 100 
min in C57 mice. Studies in C57 mice have shown that d- and dl-MPH 
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produce dose-related increases in motor activity, while the I-isomer produces 
little or no stimulatory effects [40]. Thus, it is hypothesized that despite 
significantly higher 3 h brain concentrations of d-MPH following transdermal 
dosing, the total distance traveled of mice did not reach the same levels of 
early time points following oral dosing due in part to the mice habituating to 
the chambers and such low activity was not able to rebound to early activity 
levels found after oral dosing. A further explanation for the attenuated total 
distance traveled by the transdermal dl-MPH - ethanol group could pertain to 
the induction of stereotypic behaviors associated with such high brain d-MPH 
concentrations, especially in the concomitant ethanol group. This may be 
supported by the significantly higher vertical activity found at later time points 
following transdermal dosing. Further, the observation that the stimUlant 
effect of transdermal dl-MPH was not potentiated by co-administration of 
ethanol may relate to the anticipated lag phase in transdermal drug 
absorption extending well into the elimination phase of ethanol (see [115]. It is 
noted that the mean elimination half-life of ethanol in C57 mice has been 
reported to be approximately 1.3 h to 1.5 h [122, 126]. 
The 13-fold greater I-EPH concentration found in the transdermal dl-MPH 
- ethanol group relative to the oral dl-MPH - ethanol group is unlikely to 
directly contribute to the neuropharmacology of this drug combination in view 
of the inactivity of the I-isomer of EPH in vivo or in vitro [40-41]. However, the 
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/-EPH concentration may indirectly gauge the extent to which dl-MPH and 
ethanol interact with CES1. 
The presence of /-EPH in the C57 mouse brain samples offers further 
evidence that this transesterification metabolite can serve as a biomarker for 
concomitant dl-MPH - ethanol exposure [72]. Most importantly, ethanol 
significantly potentiated oral dl-MPH induced stimulant effects and elevated 
the brain d-MPH concentrations in this C57 mouse model. These findings 
could carry implications for increased abuse liability when ethanol is 




Enantioselective de-esterification of dl-MPH to ritalinic acid (top right) and 
transestification to l-ethylphenidate. 
Figure 4.2 
(A) Oral dl-MPH + dH20 significantly increased total distance traveled (*, 
p<O.05) and this effect was potentiated by a depressive dose of ethanol (+, 
p<O.05). 
(8) Oral dl-MPH significantly increased vertical activity of mice over the first 
100 min (*, p<O.05). 
Figure 4.3 
(A) Transdermal dl-MPH induced locomotor activity after a lag phase of 100 
min (**, p<O.01). While this effect was not potentiated by ethanol, 
transdermal dl-MPH + ethanol was significantly greater than placebo patch + 
dH20 after a lag phase of 140 min (++, p<O.01). 
(8) Transdermal dl-MPH significantly increased vertical activity of mice after 
100 min lag time (*, p<O.05). 
Figure 4.4 
(A&B) Ethanol significantly increased brain concentrations of d-MPH and /-
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Summary and Conclusions 
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Summary 
The purpose of the experiments in this dissertation was to develop a 
mouse model to investigate the reward value of dl-MPH and the 
pharmacokinetic and pharmacodynamic interactions with ethanol. Previous 
studies have used IP injections as a route of administration to investigate dl-
MPH and ethanol interactions, but the current studies used routes of 
administration similar to how a normal ADHD patient would consume his or 
her drugs with a particular focus on the transdermal route of administration for 
dl-MPH and oral administration of ethanol. 
In huma.ns, coadministration of dl-MPH and ethanol results in a 
significant elevation of maximum plasma d-MPH concentrations (Cmax) and 
overall d-MPH exposure [27]. Elevated plasma d-MPH concentrations 
increase the potential for adverse cardiovascular events [42-43] due to the 
fact that the d-isomer is responsible for adrenergic pressor effects. In 
addition to the influence of ethanol on dl-MPH pharmacokinetics, the above 
normal subjects reported an increase in pleasurable effects when combining 
dl-MPH with ethanol [44]. Such positive subjective effects may predispose 
individuals to greater abuse liability [32-33, 45]. 
To better understand the pharmacokinetic and pharmacodynamic 
interactions between dl-MPH and ethanol, we first established that C57 mice 
are a valid model for investigating the reward value of dl-MPH. We then used 
C57 mice to investigate the following research questions: 1) To what degree 
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does ethanol influence the concentration of enantiomers of MPH and EPH in 
the brain, blood or urine of C57 mice? 2) What effect does ethanol have on 
the stimulatory effects of dl-MPH in C57 mice? 3) Is there a differential effect 
of ethanol on C57 mice dosed with oral dl-MPH versus transdermal MPH? 
Results from Specific Aim 1 confirmed that C57 mice self-administer 
dl-MPH and exhibit robust drug seeking behavior in response to the drug itself 
and conditioned cues. Previous studies using the Spontaneously 
Hypertensive Rat as a model for ADHD show that they do exhibit drug 
seeking behavior [50], however growing evidence suggests they are not an 
appropriate model for ADHD particularly in their response to first line 
therapeutics such as dl-MPH [51-52]. The C57 mouse is a widely used 
reference strain for drugs of abuse [40-41, 46, 55] and was chosen as the 
preferred model for studying dl-MPH, particularly with coadministration of 
ethanol in view of the fact that this strain prefers to consume ethanol [127]. 
The C57 mouse model has been shown to self-administer cocaine [56] and in 
the present study has been shown to quickly acquire drug seeking behavior of 
dl-MPH. In this study, self-administration is maintained despite increasingly 
difficult demands. The reward value of dl-MPH is shown through robust drug-
seeking behavior despite a two week abstinence period and the lack of drug 
reinforcement. It is further shown through the maintenance of drug seeking 
behavior despite removal of condition cues implying that drug seeking 
behavior in this study was not due to a condition response, but actually due to 
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the reward value of dl-MPH. The results of this study indicate that the C57 
mouse is an appropriate model for further studies using dl-MPH. 
Results from Specific Aim 2 indicated that ethanol significantly altered 
the pharmacokinetics of dl-MPH in C57 mice, particularly when dosing by the 
transdermal route. A quarter of the smallest commercially available MTS patch 
was used and this delivered a mean dose of -7.5 mg/kg of dl-MPH over the 
3.25 h wear period based on the difference between drug content before and 
after application. Though the MTS is not designed to be cut into portions for 
clinical applications, the dl-MPH content in each patch is evenly distributed 
throughout the patch [16] and required apportioning when using such a small 
species as the mouse. The mean dose of 0.23 mg of dl-MPH delivered to the 
mice (n = 12) over the 3.25 h wear represents 3.3% of the % patch content of 
dl-MPH and ranged from 1.9 - 5.10/0. In humans, the uncut 12.5 cm2 patch size 
is deSigned to deliver a mean dl-MPH dose of 10 mg over the recommended 9 
h wear. This dose represents 36% of the patch dl-MPH content, though 
ranging between subjects from 15-72% [89]. The apparent transdermal dl-MPH 
absorption differences reflect many factors including: (1) the shorter wear time 
of 3.25 h for the mouse, (2) the faster rate of ester substrate metabolism 
expected with rodents relative to humans [90], (3) the hair follicle rich shaved 
skin of the mice opposed to the skin surface of the recommended hip 
placement in clinical applications, and (4) the potential for a greater relative 
absorption lag time for the 3.25 h wear versus 9h in humans. In this latter 
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context, the average lag time for detectable d-MPH in plasma after applying 
MTS to humans is 3.1 h (ranging from 1-6 h)[91]. The above factors 
notwithstanding, it is recognized that the percutaneous absorption rate for a 
range of drugs in mice and other rodents has generally been found to be more 
rapid than in humans or pigs [92]. 
Our studies with mice dosed with oral dl-MPH+dH20, while being limited to 
a single 3 h time point for blood and brain sampling, suggest a lower degree of 
metabolic enantioselectivity relative to humans, whereby the d-MPH-to-I-MPH 
ratio for blood and brain were 1.22 and 1.36, respectively. This apparent 
greater oral bioavailability of I-MPH in the C57 mouse than in man is in general 
agreement with plasma results using CD1 mice dosed at 5.0 mg/kg [86] or 
pregnant rats dosed at 7.0 mg/kg [87]. Further, the extent of accumulation in 
brain relative to blood will be expected to be less dramatic at 3 h than at earlier 
time points, especially after oral dosing were the decay time course to resemble 
that of the Sprague-Dawley rat [77]. 
Based on human investigations [27], and the present findings with C57 
mice, the enantioselective formation of /-EPH following co-administration of 
dl-MPH and ethanol is accompanied by an elevation in d-MPH concentrations 
relative to dosing with dl-MPH alone. While /-EPH formation was found to be 
enantioselective, this metabolic pathway was not enantiospecific, i.e., /-EPH 
concentrations significantly exceeded d-EPH values though d-EPH was 
readily detectable and quantifiable in C57 mouse samples following MTS and 
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ethanol, as well as in the urine of animals dosed orally with dl-MPH. In 
humans dosed orally with dl-MPH and ethanol, d-EPH rarely exceeded 100/0 
of the concentration of I-EPH [27]. In potential forensic medicine applications 
[72], detection of EPH from biological samples could serve as a biomarker to 
demonstrate combined consumption of dl-MPH and ethanol; analogous to the 
detection of cocaethylene as evidence of cocaine - ethanol coabuse [100]. In 
view of the significant influence of ethanol on d-MPH concentrations in the 
C57 mouse model reported here, transdermal dl-MPH used to treat adult 
ADHD may be associated with clinical considerations unique to this route of 
administration, should drug interaction findings from of this animal model hold 
for humans. 
Results from Specific Aim 3 indicated that that a depressive dose of 
ethanol potentiates a stimulatory dose of oral dl-MPH. This provides 
additional insight into the reward value associated with dl-MPH - ethanol co-
abuse (see [18] and [115]). The ethanol -mediated increases in d-MPH brain 
concentrations found following oral dosing, and the potentiated behavioral 
effects, carry special abuse liability implications for the dl-MPH - ethanol 
combination [18]. 
The significantly lower total distance traveled of mice dosed with 
transdermal MPH compared to oral dl-MPH is likely due to the lag phase in 
transdermal drug absorption [16] as well as the fact that locomotor activity of 
mice decreases over time. It is hypothesized that despite significantly higher 
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3 h brain concentrations of the d-isomer of MPH following transdermal dosing, 
the total distance traveled of mice (while significant compared to transdermal 
dl-MPH + dH20) did not reach the same levels of early time points following 
oral dosing due to the fact that mice had reached such low activity that the 
rebound effect was not able to reach levels found after oral dosing. A further 
explanation could be potential stereotypic behaviors associated with such 
high brain d-MPH concentrations and may be reflected in the significantly 
higher vertical activity found at later time points following MTS dosing. 
Further, the observation that the stimulant effect of transdermal dl-MPH was 
not potentiated by co-administration of ethanol is interpreted as a lag phase in 
transdermal dl-MPH drug overlapping the elimination phase of the oral 
ethanol (see [115]). 
The presence of I-EPH in the C57 mouse brain samples offers further 
evidence that this transesterification metabolite can serve as a biomarker for 
concomitant dl-MPH - ethanol exposure [72]. 
The results from these studies in combination with human clinical data 
indicate that concomitant ethanol significantly alters the pharmacokinetics and 
pharmacodynamics of dl-MPH alone. These interactions have significant 
implications for abuse liability and toxicity and should be considered before 
prescribing the stimulant medication dl-MPH to an adult population. 
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